

論 文

< 欧文 >

1. Tanaka Y.
State-of-the-art treatment of systemic lupus erythematosus.
Int J Rheum Dis (2020) 23, 465–471
2. Tanaka Y, Izutsu H.
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Expert Opin Pharmacother. (2020) 21: 1015–1025
3. Tam L-S, Tanaka Y, Handa R, Chang C-C, Cheng YK, Isalm N, Li M, Lorenzo JP, Song Y-W, Yamamoto K, Zeng X, Haq SA.
Care for patients with rheumatic diseases during COVID-19 pandemic - a position statement from APLAR.
Int J Rheum Dis (2020) 23, 717–722
4. Tanaka Y.
A review of upadacitinib in rheumatoid arthritis.
Mod Rheumatol (2020) 30: 779–787
5. Yamagata K, Nakayamada S, Tanaka Y.
Critical roles of super-enhancers in the pathogenesis of autoimmune diseases.
Inflamm Regen (2020) 40:16. doi: 10.1186/s41232-020-00124-9.
6. Tanaka Y.
Rheumatoid arthritis.
Inflamm Regen (2020) 40:20. doi: 10.1186/s41232-020-00133-8)
7. Miyagawa I, Tanaka Y.
The approach to precision medicine for the treatment of psoriatic arthritis.
Immunol Med (2020) 43: 98–102
8. Tsujimura S, Kawabe A, Tanaka Y.
P-glycoprotein expressing-B cell associated active true renal lupus vasculitis in lupus nephritis.
Lupus: Open Access (2020) 5:150. DOI: 10.35248/2684-1630.20.5.150
9. Tanaka Y, Hoshino-Negishi K, Kuboi Y, Tago F, Yasuda N, Imai T.
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.
ImmunoTargets Ther (2020) 9: 241–253

10. Miyagawa I, Kubo S, Tanaka Y.
A wide perspective of targeted therapies for precision medicine in autoimmune diseases.
Expert Review of Precision Medicine and Drug Development (2020) 5, 447–453
11. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Ann Rheum Dis (2021) 80: 71–87
12. Tanaka Y, Tummala R.
Anifrolumab, a Monoclonal Antibody to the Type I Interferon Receptor Subunit 1, for the Treatment of Systemic Lupus Erythematosus: An Overview From Clinical Trials.
Mod Rheumatol (2021) 31, 1–12
13. Emery P, Durez P, Hueber AJ, de la Torre I, Larsson E, Holzkämper T, Tanaka Y.
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis - a comprehensive review.
Arthritis Res Ther (2021) 23(1):3. doi: 10.1186/s13075-020-02379-6
14. Tanaka S, Tanaka Y:
RANKL as a therapeutic target of rheumatoid arthritis.
J Bone Miner Metabolism (2021) 39, 106–112
15. Schett G, Tanaka Y, Isaacs J.
Why remission is not enough: underlying disease mechanisms in RA that prevent cure.
Nature Reviews Rheumatology (2021) 17: 135–144
16. Tanaka Y.
Managing osteoporosis and joint damage in patients with rheumatoid arthritis: an overview.
J Clin Med (2021) 10, 1241. <https://doi.org/10.3390/jcm10061241>
17. Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB.
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Mod Rheumatol (in press)

18. Tanaka Y, O'Neill S, Li M, Tsai I-C, Yang Y-W.
Systemic Lupus Erythematosus: Targeted literature review of the epidemiology, current treatment and disease burden in the Asia Pacific region.
Arthritis Care Research (in press)
19. Tsujimura S, Tanaka Y.
Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments.
Immunol Med (in press)
20. Burden AM, Tanaka Y, Xu L, Ha Y-C, McCloskey E, Cummings SR, Gluer CC.
Osteoporosis case ascertainment strategies in European and Asian countries: A comparative review.
Osteoporosis Int (in press)
21. Winthrop KL, Tanaka Y, Lee EB, Wollenhaupt J, Al Enizi A, Azevedo VF, Curtis JR.
Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review.
Clin Exp Rheumatol (in press)
22. Hao H, Nakayamada S, Tanaka Y.
Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases.
Inflamm Regen (in press)
23. Tam L-S, Tanaka Y, Handa R, Li Z, Lorenzo J-P, Louthrenoo W, Hill C, Pile K, Robinson PC, Dans LF, Hsu -Y, Lee S-M, Cho J, Hasan ATMT, Salim B, Samreen S, Shaharir S-S, Wong P, Chau J, Danda D, Haq SA.
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.
Int J Rheum Dis (in press)
24. Sugihara T, Hasegawa H, Uchida H, Yoshifuji H, Watanabe Y, Amiya e, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M.
Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.
Arthritis Res Ther (2020) 22: 72. doi: 10.1186/s13075-020-02171-6
25. Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Inoue Y, Ueno M, Okubo N, Fujita Y, Tanaka Y.
The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.

Int J Rheum Dis (2020) 23, 549–558

26. Kubo S, Siebuhr A-S, Bay-Jensen A-C, Juhl P, Karsdal MA, Satoh Y, Todoroki Y, Nakano S, Nakayamada S, Tanaka Y.

Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis.

Int J Rheum Dis (2020) 23, 532–539

27. Emery P, Tanaka Y, Cardillo T, Schlichting D, Rooney T, Beattie S, Helt C, Smolen JS.

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.

Arthritis Res Ther (2020) 22:114. doi: 10.1186/s13075-020-02199-8

28. Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T.

The development of quality indicators for systemic lupus erythematosus using electronic health data: a modified RAND appropriateness method.

Mod Rheumatol (2020) 30: 525–531

29. Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T. Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A post-hoc analysis of the SURPRISE study.

Mod Rheumatol (2020) 30: 442–449

30. Tanaka Y, Mimori T, Yamanaka H, Sunaga N, Morita K, Kimura J, Takeuchi T.

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥ 12 mg/week methotrexate for early rheumatoid arthritis: results of the HAWK postmarketing surveillance study in Japan.

Mod Rheumatol (2020) 30: 424–433

31. Nakamura T, Satoh-Nakamura T, Nakajima A, Kawanami T, Sakai T, Fujita Y, Iwao H, Miki M, Masaki Y, Okazaki T, Ishigaki Y, Kawano M, Yamada K, Matsui S, Saeki T, Kamisawa T, Yamamoto M, Hamano H, Origuchi T, Hirata S, Tanaka Y, Tsuboi H, Sumida T, Okazaki K, Tanaka M, Chiba T, Mimori T, Umehara H. Impaired expression of innate immunity-related genes in IgG4-related disease (IgG4-RD): A possible mechanism in the pathogenesis of IgG4-RD.

Mod Rheumatol (2020) 30: 551–557

32. Torimoto K, Okada Y, Tanaka Y, Matsuoka A, Hirota Y, Ogawa W, Saisho Y, Kurihara I, Itoh H, Inada S,

- Koga M.
Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening.
Endocrine J (2020) 67, 509–513
33. Kawabe A, Nakano K, Kubo S, Tanaka Y.
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Arthritis Res Ther (2020) 22: 136
34. Miyazaki Y, Nakayamada S, Kubo S, Ishikawa Y, Yoshikawa M, Sakata K, Iwata S, Miyagawa I, Nakano S, Tanaka Y.
Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Arthritis Res Ther (2020) 22: 141
35. Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T.
Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: A multicenter, randomized, comparative study.
J Bone Miner Metabolism (2020) 38, 511–521
36. Zhang M, Iwata s, Hajime M, Ohkubo N, Todoroki Y, Miyata H, Ueno M, Hao H, Zhan T, Nakayamada S, Yamagaata K, Tanaka Y.
Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase enhancer of zeste homolog 2.
Arthritis Rheumatol (2020) 72, 1143–1153
37. Matsumoto, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Matsumoto T.
Eldecalcitol is more effective than alfacalcidol in increasing bone mineral density in patients with glucocorticoid-induced osteoporosis: A multicenter, randomized, open-label study (e-GLORIA).
J Bone Miner Metabolism (2020) 38, 522–532
38. Tanaka Y, Soen S, Ishiguro N, Yamanaka H, Yoneda T, Tanaka S, Ohira T, Nitta T, Okubo N, Genant HK, van der Heijde D, Takeuchi T.
Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
RMD Open (2020) 6: e001249
39. Kitanaga Y, Imamura E, Nakahara Y, Fukahori H, Fujii Y, Kubo S, Nakayamada S, Tanaka Y.

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.

Rheumatology (2020) 59, 1957–1968

40. Yamagata K, Nakayamada S, Zhan T, Zhang X, Tanaka Y.
Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis.
Clin Exp Rheumatol (2020) 38, 670–679
41. Tokutsu A, Okada Y, Torimoto K, Tanaka Y.
Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; A pilot study.
Diabetology & Metabolic Syndr (2020) 12: 70. doi: 10.1186/s13098-020-00577-5
42. Ishimaru T, Fujino Y, Anzai T, Matsuda S, Tanaka Y.
Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: a multicenter prospective study.
Mod Rheumatol (2020) 30, 821–827
43. Yamaguchi A, Hirata S, Kubo S, Fukuyo S, Hanami K, Nakano K, Nakayama S, Saito K, Tanaka Y.
5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Mod Rheumatol (2020) 30, 799–806
44. Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niuro H, Tamura N, Banno s, Yoshifuji H, Sakata Y, Kawakami a, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, okada N, Yamakido S, Takei S, Yokota S, Nishimoto T
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomised controlled phase 3 TAKT study.
Rheumatology (2020) 59: 2427–2434
45. Johnson SR, Brinks R, Costenbader K, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirjak L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M.
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early

disease, across sexes and ethnicities.

Ann Rheum Dis (2020) 79, 1333–1339

46. Goshima Y, Okada Y, Torimoto K, Fujino Y, Tanaka Y.
Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus.
Sci Rep (2020) Sep 21;10(1):15384. doi:10.1038/s41598-020-72341-8
47. Lee S, Nakayama S, Kubo S, Yamagat K, Yoshinari H, Tanaka Y.
IL-23 drives expansion of Th17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients.
Rheumatology (2020) 59: 3058–3069
48. Dörner T, Tanaka Y, Petri M, Smolenn JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW.
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Lupus Sci Med (2020) 7(1):e000424. doi: 10.1136/lupus-2020-000424
49. Strand V, van der Heijde D, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song Y, Tegzoba D, Gruben D, Wallenstein G, Connell CA, Fleischmann R, ORAL Scan investigators.
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient reported outcomes from the 24-month Phase 3 ORAL Scan study.
Clin Exp Rheumatol (2020) 38(5):848–857
50. Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman A, Pangan A, Kitamura S, Meerwein S, Tanaka Y.
Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase 2b/3 study.
Rheumatology (2020) 59: 3303–3313
51. Takeuchi T, Tanaka Y, Erdman J, Kaneko Y, Saito M, Higashiani C, Smulders R, Lademacher C.
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: Results from a phase 2a, randomized, double-blind, placebo-controlled trial.
Arthritis Res Ther (2020) 22(1):252. doi: 10.1186/s13075-020-02336-3
52. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J.
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis

clinical development programme.

RMD Open (2020) 6(3):e001395. doi: 10.1136/rmdopen-2020-001395

53. Tanaka Y, Kondo K, Ichibori A, Yoshinari T, Susuta Y, Inoue S, Takeuchi T.
Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: a multicenter, open-label exploratory study.
Lupus (2020) 29, 1920–1913
54. Sonoda S, Okada Y, Torimoto K, Sugai K, Uemura F, Tanaka K, Hajime M, Mori H, Tanaka Y.
Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes Mellitus.
J UOEH (2020) 42, 299–306
55. Iwata S, Zhang M, Hao H, Trimova G, Hajime M, Miyazaki Y, Okubo N, Todoroki Y, Miyata H, Ueno M, Nagayasu A, Nakayamada S, Sakata K, Tanaka Y.
Enhanced fatty acid synthesis leads to subset imbalance and IFN- γ overproduction in T helper 1 cells.
Front Immunol (2020) 11:593103. doi: 10.3389/fimmu.2020.593103
56. Cho J, Kandane-Rathnayake R, Louthrenoo W, Hoi A, Golder V, Chen YH, Luo SF, Wu YJ, Hamijoyo L, Lau CS, Navarra S, Zamora L, Tee M, Flora A Jr, Li ZG, An Y, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Basnayake D, Goldblatt F, Chan M, Ng KPL, Bae SC, Oon S, O'Neill S, Gibson K, Kumar S, Law AHN, Tugnet N, Tanaka Y, Nikpour M, Morand E, Lateef A.
COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration.
Int J Rheum Dis (2020) 23, 1255–1257
57. Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, Tanaka Y.
Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE Modern Rheumatology.
Mod Rheumatol (2021) 31, 34–41
58. Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, Itoh Y, Yasuoka H, Fukaya S, Ashihara K, Hirano D, Ohmura K, Tabuchi Y, Hasegawa H, Matsumiya R, Shirai Y, Ogura T, Tsuchida Y, Ogawa-Momohara M, Narazaki G, Inoue Y, Miyagawa I, Nakano K, Hirata S, Mori M.
2019 diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan Research Committee of the Ministry of Health, Labor, and Welfare for systemic autoimmune diseases.
Mod Rheumatol (2021) 31, 29–33
59. Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, Tamura N, Fujio K, Fujii T, Kojima T, Anzai

- T, Hamada C, Fujino Y, Matsuda S, Kohsaka H.
Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC Study.
Mod Rheumatol (2021) 31, 42-52
60. Takeuchi T, Tanaka Y, Higashitani C, Iwai M, Komatsu K, Akazawa R, Lademacher C.
A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate.
Mod Rheumatol (2021) 31, 53-60
61. Nakano K, Saito K, Nawata A, Hanami K, Kubo S, Miyagawa I, Fujino Y, Nakayama S, Tanaka Y.
Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Mod Rheumatol (2021) 31, 94-100
62. Hao H, Nakayama S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, Zhang M, Zhang T, Satoh-Kanda Y, Shan Y, Otsuka T, Tanaka Y.
IL-2 drives conversion of T follicular helper cells to T follicular regulatory cells through transcriptional regulation in systemic lupus erythematosus.
Arthritis Rheumatol (2021) 73, 132-142
63. Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, Pangan AL, Konishi Y, Meerwein S, Tanaka Y.
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
Arthritis Res Ther (2021) 23(1):9. doi: 10.1186/s13075-020-02387-6
64. Narisawa M, Kubo S, Okada Y, Yamagata K, Nakayama S, Sakata K, Yamaoka K, Tanaka Y.
Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability.
Bone (2021) Jan;142:115616. doi: 10.1016/j.bone.2020.115616
65. Aletaha D, Bingham III CO, Karpouzias G, Takeuchi T, Thorne C, Bili A, Agarwal P, Jsu B, Rao R, Brown K, Tanaka Y.
Long-term Safety and Efficacy of Sirukumab for Patients With Rheumatoid Arthritis Who Previously Received Sirukumab in Randomized Controlled Trials (SIRROUND-LTE).
RMD Open (2021) 7:e001465. doi:10.1136/rmdopen-2020-001465
66. Cohen SB, van Vollenhoven R, Winthrop K, Zerbini CAF, Tanaka Y, Bessette L, Zhan Y, Khan N,

- Hendrickson B, Enejosa JV, Burmester GR.
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical programme.
Ann Rheum Dis (2021) 80, 304–311
67. Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, Gottenberg JE, Bergstra SA, Suarez MP, Codreanu C, Kvien TK, Santos MJ, Pavelka K, Hetland ML, Askling J, Turesson C, Kubo S, Tanaka Y, Iannone F, Choquette D, Nordström DC, Rotar Z, Lukina G, Gabay C, Van Vollenhoven R, Finckh A.
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
Rheumatology (2021) 60: 820–828
68. Uemura F, Okada Y, Torimoto K, Tanaka Y.
Enlarged glycemic variability in sulfonyleurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
Sci Rep (2021) 11:4875 doi.org/10.1038/s41598-021-83999-z
69. Ueno M, Miyagawa I, Nakano K, Iwata S, Hanami K, Fukuyo S, Kubo S, Miyazaki Y, Kawabe A, Yoshinari H, Nakayamada S, Tanaka Y.
Effectiveness and Safety of Mepolizumab in Combination with Corticosteroids in patients with Eosinophilic Granulomatosis with Polyangiitis.
Arthritis Res Ther (2021) 23: 86. doi: 10.1186/s13075-021-02462-6
70. Ishikawa Y, Nakano K, Tokutsu K, Miyata H, Fujino Y, Matsuda S, Tanaka Y.
Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases.
RMD Open (2021) 7: e001508. doi: 10.1136/rmdopen-2020-001508
71. Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T.
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis with Inadequate Response to Methotrexate.
Arthritis Rheumatol (2021) 73, 587–595
72. Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, Kato D.
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Mod Rheumatol (2021) 31, 543–555
73. Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song YW, Chen YH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y.

Safety and Effectiveness of Peficitinib (ASP015K) in Patients With Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.

Rheumatol Ther (2021) 8: 425–442

74. Conaghan PG, Mysler E, Tanaka Y, Da Siva-Tillmann B, Shaw T, Liu J, Ferguson R, Enejosa JV, Cohen S, Nash P, Rigby W, Burmester G.

Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program.

Drug Safety (2021) 44: 515–530

75. Tanaka K, Okada Y, Hajime M, Mori H, Tanaka Y.

Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.

J Diabetes Investig (in press)

76. Smolen JS, Xie L, Jia B, Taylor PC, Burmester G, Tanaka Y, Elias A, Cardoso A, Ortmann R, Walls C, Dougados M.

Efficacy of baricitinib in patients with rheumatoid arthritis with three years of treatment: Results from a long-term study.

Rheumatology (in press)

77. Tanaka Y, Millson D, Iwata S, Nakayamada S.

Safety and Efficacy of Fostamatinib in RA Patients with an Inadequate Response to MTX in Phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study.

Rheumatology (in press)

78. Tanaka I, Tanaka Y, Soen S, Oshima H.

Efficacy of Once-Weekly Teriparatide in Patients with Glucocorticoid-Induced Osteoporosis: The TOWER-GO Study.

J Bone Miner Metabolism (in press)

79. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Suzuki Y.

Treatment of Rheumatoid Arthritis After Regression of Lymphoproliferative Disorders: A Retrospective, Multi-center Descriptive Study.

Mod Rheumatol (in press)

80. Tanaka K, Okada Y, Hajime M, Tanaka Y.

Low vitamin D levels are associated with poor vascular endothelial function in patients with type 2 diabetes: A retrospective study.

J Atheroscler Thromb (in press)

81. Takeuchi T, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoaka K, Genovese MC, Kalunian K, Walker D, Gottenberg J, de Vlam K, Bartok B, Pechonkina A, Kondo A, Gao J, Guo Y, Tasset C, Sunday JS, Tanaka Y.

Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global Phase 3 study (FINCH 2).

Mod Rheumatol (in press)

82. Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T.

A phase 2 study of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological Disease-modifying antirheumatic drug.

Mod Rheumatol (in press)

83. Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundry JS, Jahreis A, Genovese MC, Mozaffarian N, Landewe RBM, Bae SC, Keystone E, Nash P.

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase 3 randomised clinical trial.

Ann Rheum Dis (in press)

84. Tanaka Y, Okamura H, Kim S, Dorey J, Wojciechowski P, Chorazy J, Kato D, Schultz NM.

Comparative efficacy and safety of peficitinib versus tofacitinib and baricitinib for treatment of rheumatoid arthritis: a systematic review and network meta-analysis.

Rheumatol Ther (in press)

85. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerström K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader K, Johnson SR.

European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE Classification Criteria Item Performance.

Ann Rheum Dis (in press)

86. Ochi S, Mizoguchi F, Nakano K, Tanaka Y.

Difficult-to-treat RA with respect to responsiveness to biologic/targeted synthetic DMARD: from the FIRST registry.

Clin Exp Rheumatol (in press)

87. Mok CC, Hamijoyo L, Nuntana K, Chen DY, Chen S, Yamaoka K, Oku K, Tao M, Zamora L, Bae SC, Navarra S, Morand E, Tanaka Y.

The Asia Pacific League of Associations for Rheumatology (APLAR) consensus statements on the management of systemic lupus erythematosus.

Lancet Rheumatology (in press)

88. Iwata S, Zhang M, Hajime M, Ohkubo N, Sonomoto K, Torimoto K, Kitanaga Y, Trimova G, Todoroki Y, Miyata H, Ueno M, Nakagasy A, Kanda R, Nakano K, Nakayamada S, Sakata K, Tanaka Y.

Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis.

Rheumatology (in press)

89. Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y, Tanaka Y.

Efficacy and safety of tofacitinib vs. baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.

Ann Rheum Dis (in press)

90. Tanaka Y, Takeuchi T, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D.

Effects of denosumab in Japanese rheumatoid arthritis patients treated with conventional anti-rheumatic drugs: 36-month extension of a phase 3 study.

J Rheumatol (in press)

91. Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T.

The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan.

Drug Safety (2021) 44: 515–530

92. Tokutsu A, Okada Y, Torimoto K, Tanaka Y.

Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study.

Diabetology & Metabolic Syndrome (2021) 13(1):45

93. Tokutsu A, Okada Y, Torimoto K, Kurozumi A, Narisawa M, Tanaka Y.

Relationship Between Blood Glucose Variability in the Ambulatory Glucose Profile and Standardized Continuous Glucose Monitoring Metrics.

Diabetol Metab Syndr (2020) 12:70

94. Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima K, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Ueda S, Higashi Y, Node K.
Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: the placebo-controlled double-blind randomized EMBLEM trial.
J Diabetes Investig (2020) 11(6): 1551–1563
95. Wakasugi S, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Kuribayashi N, Taneda Y, Kojima Y, Goshō M, Shimomura I, Watada H.
Associations between continuous glucose monitoring-derived metrics and arterial stiffness in patients with type 2 diabetes mellitus.
Cardiovasc Diabetol (2021) 20(1):15
95. Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T, and the J-BRAND Registry Group.
Long-term Safety and Efficacy of Alogliptin, a DPP-4 Inhibitor, in Patients with Type 2 Diabetes: A 3-year Prospective, Controlled, Observational Study (J-BRAND Registry).
BMJ Open Diabetes Research & Care (2021) 9(1):e001787
97. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I, on behalf of the UTOPIA study investigators.
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Cardiovasc Diabetol (2021)20(1):4
98. Kurozumi A, Okada Y, Tanaka Y.
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by flash glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Endocrine J (2021) 68(3): 361–369
99. Sugito M, Okada Y, Torimoto K, Enta K, Tanaka Y.
Work environment-related stress factors correlate with the development of diabetes in workers with impaired glucose tolerance: A 5-year follow-up study.
J UOEH (in press)
100. Wakasugi S, Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Torimoto K, Kurozumi A, Goshō M, Shimomura I, Watada H.

Associations between continuous glucose monitoring derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus.

BMJ Open Diabetes Research & Care (in press)

101. Taya N, Katakami N, Mita T, Okada Y, Wakasugi S, Yoshii H, Shiraiwa T, Otsuka A, Umayahara Y, Ryomoto K, Hatazaki M, Yasuda T, Yamamoto T, Gosho M, Shimomura I, Watada H.
Associations of Glucose Variability with Intima-Media Thickness and Ultrasonic Tissue Characteristics of the Carotid Arteries: A Cross-Sectional Analysis in Patients with Type 2 Diabetes.
Cardiovasc Diabetol (in press)
102. Nagayasu A, Nawata M, Saito K, Tanaka Y.
Short-term effectiveness of Ixekizumab to refractory psoriatic arthritis with spondyloarthritis: Two case reports.
Mod Rheumatol Case Reports (2020) 4, 175-180
103. Kanda R, Nakano K, Miyagawa I, Iwata S, Nakayamada S, Tanaka Y.
A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumor necrosis factor- α (TNF- α) inhibitor, adalimumab.
Mod Rheumatol Case Reports (2020) 4, 196-201
104. Funada M, Nakano K, Miyagawa I, Ueno M, Tanaka Y.
Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report.
Mod Rheumatol Case Reports (2020) 4, 229-232
105. Kusaka K, Nakano K, Iwata S, Kubo S, Nishida T, Tanaka Y.
Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators.
Mod Rheumatol Case Reports (2020) 4, 253-261
106. Kanda R, Kubo S, Nakano K, Kawabe A, Nawata A, Hanami K, Nakayamada S, Tanaka Y.
A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related diseases.
Mod Rheumatol Case Reports (2020) 4, 278-282
107. Ueno M, Nakano K, Miyagawa I, Tanaka Y.
Five cases of IgG4-related diseases with nasal mucosa and sinus involvements.
Internal Med (2020) 59, 1905-1911
108. Hashimoto R, Katsuki A, Fujita Y, Ikenouchi A, Tanaka Y, Yoshimura R.
A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various

psychiatric symptoms and MRI observations.

Clinical Neuropsychopharmacology and Therapeutics (2020) 11, 1–4

109. Tokutsu A, Okada Y, Torimoto K, Otsuka T, Narisawa M, Kurozumi A, Tanaka Y.
Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases.
Neuro Endocrinol Lett (2020) 41,1: 10–16
110. Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K:
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Cardiovasc Diabetol 19(1):85, 2020
111. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I.
Effect of tofogliflozin on carotid intima-media thickness in patients with type 2 diabetes: results from the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Cardiovasc Diabetol (2020)9;19(1):110
112. Ohkubo N, Nakano K, Miyagawa I, Tanaka Y.
Mild encephalitis/encephalopathy with reversible splenial lesion in SLE.
Internal Med (2020) 59: 2439–2440
113. Koikawa K, Okada Y, Torimoto K, Tanaka Y.
A Case of Hyperparathyroidism Manifesting After Resection of a Fibroblast Growth Factor 23-producing Tumor.
Internal Med (2020) 59: 2523–2527
114. Nawata M, Nagayasu A, Fujita Y, Nawata A, Saito K, Tanaka Y.
Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: a novel case report.
Lupus (2020) 29, 1955–1960
115. Kurozumi A, Okada Y, Miyazaki Y, Nakayamada S, Tanaka Y.
Fulminant type 1 diabetes with diversity in peripheral blood lymphocytes: a case report.
J UOEH (2020) 42, 57–62
116. Funada M, Nawata M, Nawata A, Miyamoto T, Saito K, Tanaka Y.

Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report.

Mod Rheumatol Case Reports (2021) 5: 11–15

117. Nishida T, Nakano K, Inoue Y, Akashi K, Tanaka Y.

A case of STING-associated vasculopathy with onset in infancy diagnosed after development of atypical pulmonary lesions during treatment as juvenile idiopathic arthritis.

Internal Med (2021) 60: 1109–1114

118. Tanaka Y, Sato-Kanda Y, Yoshinari H, Nakano K, Shimajiri S, Sato M.

Lung-transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: A case report.

Rheumatology (Oxford) (2021) 60: e129–e131

119. Imabayashi K, Nakano K, Iwata S, Tanaka Y.

A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension.

Mod Rheumatol Case Reports (in press)

120. Nawata A, Nakamura A, Taba M, Kosaka S, Kawabe A, Miyata H, Matsuki Y, Tanaka Y, Hosapla M.

Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: An autopsy case report.

CEN Case Reports (in press)

121. Kurozumi A, Okada Y, Nishio K, Tanaka Y.

A case of autoimmune polyendocrine syndrome type 3 (APS-3) complicated with anti-N-methyl-D-aspartic acid-receptor (NMDA-R) encephalitis.

J Diabetes Investig (2021) 12(2) 290–292

<邦文>

1. 田中良哉
ステロイド性骨粗鬆症の診断と治療
老年内科 (2020) 1, 444-452
2. 中山田真吾、宮川一平、久保智史、田中良哉
末梢血リンパ球サブセットによる病態解析と臨床応用
Current Therapy (2020) 38, 467-472
3. 田中良哉
JAK 阻害薬の最新研究: 2年間の関節破壊抑制効果からみた適正使用
Joint and Kinase Frontier (2020) 4, 2-7
4. 中山田真吾, 田中良哉
SLE における濾胞性ヘルパーT細胞のエピゲノム制御.
臨床免疫・アレルギー科 (2020) 73, 249-256
5. 中山田真吾, 田中良哉
SLE における濾胞性ヘルパーT細胞の分化と機能.
リウマチ科. (2020) 63, 176-183
6. 中山田真吾、田中良哉
IgG4 関連疾患の末梢血リンパ球フェノタイプ
Current Therapy (2020) 38, 737
7. 田中良哉、久保智史、井上嘉乃、中山田真吾
IgG4 関連疾患における免疫細胞とサイトカイン
炎症と免疫 (2020) 28, 304-309
8. 岡田洋右、田中良哉
第 10 章 特殊な病態と関連する骨粗鬆症 2.ステロイド性骨粗鬆症
糖尿病・内分泌代謝科 特別増刊号 骨粗鬆症のすべて (2020) 51, 220-227
9. 田中良哉
抗リウマチ薬と骨粗鬆症
糖尿病・内分泌代謝科 (2020) 51, 243-249
10. 中山田真吾、宮崎佑介、田中良哉.
ヒト免疫細胞のマルチカラーフローサイトメトリー解析.

炎症と免疫(2020)28, 430-434

11. 田中良哉
ステロイド性骨粗鬆症.
診断と治療(2020)108, 1159-1166
12. 田中良哉
難治性リウマチ・免疫疾患治療の最前線
日本内科学会雑誌 (2020) 109, 1748-1757
13. 田中良哉
骨粗鬆症:最新の知見に基づいた治療薬の考え方・使い方
薬局 (2020) 71, 3250-3251
14. 田中健一、岡田洋右、田中良哉
徹底解説! 治療薬を使いこなす“知識”と“ノウハウ”-⑤
副甲状腺ホルモン・PTHrP アナログ(テリパラチド、abaloparatide)
薬局 (2020) 71, 3292-3297
15. 中野和久、田中良哉
関節リウマチ×骨粗鬆症
薬局 (2020) 71, 3323-3328
16. 田中良哉
生物学的製剤を含めた分子標的療法
日本医師会雑誌 (2020) 149, S144-S150
17. 久保智史、田中良哉
強皮症における微小血管障害を見える化する
medicina (2020) 57, 2102-2105
18. 岩田慈、田中良哉
全身性エリテマトーデスにおける適応免疫と治療への展望
リウマチ科 (2020) 64, 518-525
17. 田中良哉
ステロイド性骨粗鬆症
日本臨床 (2020) 78, 2115-2122
18. 田中良哉

関節リウマチ治療 update

CLINICIAN(2020)685, 2-8

19. 岩田慈、田中良哉

ヒトB細胞分化におけるアミノ酸を介した免疫代謝機構の解明: SLE 新規治療の創出
アレルギーの臨床(2021)41, 142-146

20. 田中良哉

免疫フェノタイプによるリウマチ性疾患のプレジジョン・メディシン
臨床リウマチ (2020) 32, 340-309

21. 中山田真吾、田中良哉

ループス腎炎のマネジメント: 2019年EULAR/ERA-EDTAリコメンデーション
リウマチ科 (2021) 65, 226-232

22. 宮川一平、田中良哉

乾癬性関節炎.
炎症と免疫(2021)29, 171-173

23. 中山田真吾、宮川一平、田中良哉

生物学的製剤の使い分け
日本臨床 (2021) 79, 571-576

24. 中野和久、田中良哉

滑膜研究の進歩
九州リウマチ (2021) 41, 17-19

25. 小柳徳子、中野和久、田中良哉

当院における分子標的療法中の関節リウマチ患者介護の現状と課題
九州リウマチ (2020) 40, 84-87

26. 新生忠司、岡田洋右、黒住旭、財津日奈子、五島麻里子、浦野美紀、豊福律子、亀田敬子、末松直子、田中良哉

2型糖尿病患者における週末2泊3日糖尿病短期教育パス入院による血糖コントロール改善効果に関する検討
糖尿病プラクティス (2021) 38, 245-250

27. 小坂峻平、中野和久、宮崎佑介、中山田真吾、岩田慈、河邊明男、吉成紘子、田中良哉

家族生地中海熱(FMF)非典型例としてのカナキムマブ治療中にベーチェット病の症状が顕性化しアダリムマブが奏功した一例
九州リウマチ (2020) 40:105-110

28. 羽生桃子、岡田洋右、黒住旭、田中良哉
Flash Glucose Monitoring で SGLT2 阻害薬の短期的血糖改善効果が確認できた外来通院中 1 型糖尿病の
2 症例
産業医科大学雑誌 (2020) 42, 359-364
29. 西尾公佑、岡田洋右、黒住旭、田中良哉
悪性黒色腫に対するニボルマブ投与後に破壊性甲状腺炎と ACTH 単独欠損症を来した 1 例
産業医科大学雑誌 (2021) 43, 97-102
30. 有富貴史、名和田雅夫、船田将史、齋藤和義、田中良哉
トシリズマブに対する infusion reaction 後に再投与により寛解導入・維持が可能であった成人スチル病の 1 症例
九州リウマチ (2021) 41:55-60
31. 藤田悠哉、中野和久、玉城泰太郎、吉成紘子、岩田慈、福輿俊介、宮川一平、中山田真吾、田中良哉
感染性関節炎を合併した全身性エリテマトーデスに対してセクキヌマブが奏功した一例
九州リウマチ (2021) 41:61-66
32. 鳥本桂一、岡田洋右
Review「持続血糖測定(CGM)による血糖コントロール」の指標(コンセンサスレポートを受けて)
Calm (2020) 7: 2-8
33. 鳥本桂一、岡田洋右
特集 令和時代のインスリン療法 3-2.SGLT2 阻害薬を用いたステップダウン
月刊糖尿病 (2020) 12: 78-84
34. 田中健一、岡田洋右
生活習慣病骨折リスクに関する診療ガイド up to date 肥満、脂質異常症、OSAS.
日本骨粗鬆症学会誌 (2021) 7: 27-30